Sinphar Pharmaceutical

Sinphar Pharmaceutical, founded in 1977 in Yilan, Taiwan, operates as a prominent entity within the global pharmaceutical and healthcare sectors. The company maintains a steadfast commitment to the integration of life, health, and technology, focusing its core operations on the development of therapeutic drugs, healthcare foods, and medical beauty products. By prioritizing high-quality service and public health, Sinphar Pharmaceutical has established a robust foundation for international growth and innovation.

The organization manages its extensive operations with a workforce of 500-1,000 employees. Since its inception, the group has expanded its footprint significantly, establishing subsidiaries such as CanCap Pharmaceutical in Canada and Sinphar Tianli Pharmaceutical in China. The company’s commitment to technical excellence is evidenced by its R&D Center, which adheres to ISO17025 standards and utilizes advanced cell and molecular biology testing technologies. Meet Sinphar Pharmaceutical's team to understand the professional expertise driving these complex research and development initiatives across their global network.

Sinphar Pharmaceutical continues to advance its market position through strategic product development, including specialized pharmaceuticals and magnesium oxide compounds. With annual revenue reaching $94.6M, the firm actively conducts clinical trials for cancer drugs and other therapeutic agents across multiple international jurisdictions. By leveraging high-tech precision instruments and collaborative marketing networks, the company remains dedicated to its vision of globalized healthcare advancement. This strategic approach ensures that Sinphar Pharmaceutical maintains its status as a competitive player in the international pharmaceutical landscape while consistently meeting stringent quality requirements for its diverse product portfolio.